Abstract:Purpose: Osteoarthritis (OA) is the most prevalent form of arthritis and its impact is increasing due to the aging population and lack of effective therapies. Currently, there are no therapeutics that modify the natural history of OA, partly because of the large gaps in our understanding of the underlying molecular and cellular mechanisms of OA. Macrophage migration inhibitory factor (MIF) is a procytokine that mediates pleiotropic inflammatory effects in selected neoplasms, and inflammatory diseases (rheumatoid arthritis and ankylosing spondylitis). However, role of MIF in OA is yet to be reported. Thus, our objective was to investigate the potential role of MIF in OA in a well-established OA cohort - the Newfoundland Osteoarthritis Study (NFOAS). Methods: The study participants were derived from the NFOAS. OA patients were all end-stage knee or hip OA patients who underwent total joint replacement surgery and controls were from the same population and had NO self-reported musculoskeletal symptoms. Two previously reported functional polymorphisms in the promoter of the MIF gene (one microsatellite -794CATT5-8 and one SNP rs755662) were genotyped by TaqMan method, and the plasma concentration of the MIF protein was measured by enzyme-linked immunosorbent assay (ELISA). Further, three other frequently studied cytokines in OA including tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and interleukin-1 beta (IL-1β) were also measured in the plasma samples by ELISA. Results: A total of 232 study participants were included in the study, 119 were OA patients and 113 OA-free controls. OA patients were significantly older (65.51 ± 8.89 years vs. 58.09 ± 6.60 years), had higher BMI (32.11 ± 6.26 kg/m2 vs. 30.02 ± 4.90 kg/m2), and more males than controls (47% females vs. 62% females) (all p<0.05). The data showed that the genotypes of the two previously reported functional polymorphisms in the MIF gene were not associated with the MIF protein levels, nor associated with OA (all p>0.05). However, we found that lower MIF protein level was significantly associated with OA (4.67±2.39 ng/ml in OA vs. 7.24±4.80 ng/ml in controls; p=4.67*10-7) (Table 1). The significance remained after adjustment for age, sex, and BMI (p=2*10-6), and the association was the same for knee and hip OA. Further, we found that an increased level of all three cytokines including TNF-α, IL-6 and IL-1β was associated with OA (Table 1), which is consistent with what reported in the literature. In the multivariable analysis with logistic regression and including all four cytokines and age, sex, and BMI, we found that lower MIF protein level and higher IL-1β were independently associated with OA (all p<3.46*10-8). TNF-α and IL-6 were not significantly associated with OA in the multivariable analysis. Conclusions: Our data showed that OA patients had a significantly lower serum MIF level. A previous study also found that a lower MIF level in synovial fluid in knee OA patients compared to healthy controls. Together, these suggest that MIF might have a protective role in OA. Further, given the evidence that a higher level of MIF is associated with RA and AS, MIF may also serve as a biomarker to differentiate OA from RA and AS.

HIF-1α and MIF enhance neutrophil-driven type 3 immunity and chondrogenesis in a murine spondyloarthritis model

Deep Insight into the Role of MIF in Spondyloarthritis

Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease

CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through NF-κB signaling pathway in ankylosing spondylitis in vitro

Immunopathophysiology of Juvenile Spondyloarthritis (jSpA): The “Out of the Box” View on Epigenetics, Neuroendocrine Pathways and Role of the Macrophage Migration Inhibitory Factor (MIF)

Novel HIF-1a Inhibitor AMSP-30m Mitigates the Pathogenic Cellular Behaviors of Hypoxia-Stimulated Fibroblast-Like Synoviocytes and Alleviates Collagen-Induced Arthritis in Rats via Inhibiting Sonic Hedgehog Pathway

Novel HIF-1α Inhibitor AMSP-30m Mitigates the Pathogenic Cellular Behaviors of Hypoxia-Stimulated Fibroblast-Like Synoviocytes and Alleviates Collagen-Induced Arthritis in Rats via Inhibiting Sonic Hedgehog Pathway

Reactivation of NR4A1 Restrains Chondrocyte Inflammation and Ameliorates Osteoarthritis in Rats

Exogenous stromal cell-derived factor-1 (SDF-1) suppresses the NLRP3 inflammasome and inhibits pyroptosis in synoviocytes from osteoarthritic joints via activation of the AMPK signaling pathway

Notch‐1 and Notch‐3 Mediate Hypoxia‐Induced Activation of Synovial Fibroblasts in Rheumatoid Arthritis

HIF-1α dependent RhoA as a novel therapeutic target to regulate rheumatoid arthritis fibroblast-like synoviocytes migration in vitro and in vivo

Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies

S1P Increases VEGF Production in Osteoblasts and Facilitates Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-16-5p Expression via the c-Src/FAK Signaling Pathway in Rheumatoid Arthritis

Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders

The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models

Macrophage Migration Inhibitory Factor May Play a Protective Role in Osteoarthritis

TNF-α-mediated m 6 A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis

TNF-α-mediated m6A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis

Hypoxia-inducible factor-1α perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis.

PI3 Kinase/akt/hif-1Α Pathway is Associated with Hypoxia-Induced Epithelial–mesenchymal Transition in Fibroblast-Like Synoviocytes of Rheumatoid Arthritis

Notch signalling drives synovial fibroblast identity and arthritis pathology